AstraZeneca Q1 2015 profit dropped

Noam Stiekema

The second-largest pharmaceutical company in UK AstraZeneca Q1 2015 profit dropped, due to weaker sales of two of her most popular medicines and currency fluctuations. Part of the profits fell by 7% to 1.37 billion USD, or 1.08 dollars per share. An year ago the company reported profit of 1.47 billion USD, or 1.17 USD […]

AstraZeneca

AstraZenecaThe second-largest pharmaceutical company in UK AstraZeneca Q1 2015 profit dropped, due to weaker sales of two of her most popular medicines and currency fluctuations. Part of the profits fell by 7% to 1.37 billion USD, or 1.08 dollars per share. An year ago the company reported profit of 1.47 billion USD, or 1.17 USD per share. The total revenues in Q1 2015 amounted to 6.06 billion USD, as last year they were 40 million USD more.

Sales of two of the best selling medicines of AstraZeneca – Nexium and Crestor. fall because of the expiration of their patents. At the same time revenues from new medicines grow at a slower pace than what analysts had predicted. The sales will shrink this and next year, before the expected increase in 2017, when the new medicines will raise revenue, says AstraZeneca.

Nexium sales fell by 31% to 644 million USD in the first quarter, although it exceeded the forecast of 589 million USD.

AstraZeneca is facing difficulties in the implementation of short-term goals and the promise of CEO Pascale Soriano is to increase annual revenue of 26 billion USD last year to 45 billion USD in 2023. In this regard, currently held AstraZeneca has 72 cancer researches. It aims to present for approval AZD9291, a medicine for the treatment of lung cancer worth at 3 billion USD.

AstraZeneca seek other sources of revenue, including market partnerships. Last month, the company announced that Tokyo-based Daiichi Sankyo Co will sell in the US Movantik their medicine in exchange for 200 million USD advance and to 625 million USD of sales. Such agreements, however, may not be the best strategy, says Alistair Campbell, an analyst at Berenberg. According to him, revenues have increased due to the partial sale of some medicines, but these actions raise concerns if the company does not use long-term options to ensure short-term profits.

AstraZeneca confirmed its forecast for a decline in revenue of up to 10% in 2015 at constant exchange rates, the basic earnings per share will also be increased by up to 10% on the same basis. Soriano made a forecast of the company’s sales last year, when successfully overcame the experience of Pfizer AstraZeneca to absorb the amount of 117 billion USD. Last month, the company said that by 2023 its new cancer medicine can generate a quarter of sales, after last year they accounted for only 12%.

Read this next

Digital Assets

Sam Bankman-Fried might see his 25-year sentence halved

Sam Bankman-Fried, the founder of the failed cryptocurrency exchange FTX, was sentenced to 25 years in federal prison by a Manhattan court on Thursday. This comes after he was convicted of defrauding customers and investors, with Judge Lewis Kaplan highlighting the potential future risks posed by Bankman-Fried.

Technical Analysis

EURJPY Technical Analysis Report 28 March, 2024

EURJPY currency pair under the bearish pressure after the pair reversed down from the major resistance level 164.25, which also stopped the sharp weekly uptrend at the end of last year,

Digital Assets

BlockDAG’s Presale Hits $9.9M, MultiversX & MINA Price Predictions Show Green

Read about BlockDAG’s promising $10 prediction and insights on MultiversX Price Prediction as MINA’s potential unfolds.

Digital Assets

Rockstar Co-Founder and All-star Line Up Join Advisory Board to Take Metacade into Post Beta Orbit

Metacade, the revolutionary Web3 gaming platform, prepares to streak out of beta with a slew of ground-breaking initiatives that will redefine the way blockchain games are developed.

Retail FX

Prop firm The Funded Trader shuts down, claims relaunch in April

Prop trading firm The Funded Trader has ceased all operations, with claims for a relaunch in the near future.

Digital Assets

Ethereum-Based Tokenized Real Estate Platform USP Launches On Republic

How This Californian Startup Is Revolutionizing Real Estate Investment through Ethereum-Based Tokenization.

Digital Assets

Sui Spikes in Weekly DEX Volume, Joins Top 10 of All Blockchains

March DEX volume on Sui stands at over $2.88B – up more than 49% from February – with decentralized exchange Cetus and wholesale liquidity layer DeepBook leading.

Digital Assets

Prisma Finance suffers $10 million crypto exploit, attack ongoing

Liquid staking protocol Prisma Finance fell victim to a security exploit on March 28, resulting in nearly $10 million in Prisma mkUSD and wrapped stETH being stolen by hackers.

Digital Assets

Masa and LayerZero: Bridging Blockchains for Data Sovereignty

Masa Network is poised to revolutionize the personal data landscape with its upcoming launch as a cross-chain platform, making it accessible on a variety of blockchains right from the start.

<